• About us
• Contact

Advertisement

Product › Details

SUREtechnology Platform™ (Selexis)

	Next higher product group	rPP technology [recombinant protein production technology]
	Organisation	Selexis S.A.
	Group	JSR Corporation (Group)

Record changed: 2023-07-10

Advertisement

More documents for SUREtechnology Platform™ (Selexis)

• [1] Selexis S.A.. (3/18/21). "Press Release: SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program". Geneva....
• [2] Selexis S.A.. (10/20/20). "Press Release: JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland". Sunnyvale, CA....
• [3] Selexis S.A.. (10/16/20). "Press Release: Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer". Geneva....
• [4] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
• [5] Selexis S.A.. (6/27/17). "Press Release: Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins". Geneva....
• [6] Selexis S.A.. (6/14/17). "Press Release: JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.". Tokyo & Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.